BLU:NSD-BELLUS Health Inc

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.10

Change

-0.14 (-1.93)%

Market Cap

USD 0.39B

Volume

0.13M

Average Target Price

N/A
Average Analyst Rating

N/A

STA Verdict

Verdict

About

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Market Stats

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-09-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+2.61 (+1.49%)

USD 44.97B 20.53 41.60
REGN Regeneron Pharmaceuticals, Inc

+4.27 (+1.52%)

USD 30.93B 15.64 12.43
ALXN Alexion Pharmaceuticals, Inc

+1.14 (+1.06%)

USD 24.08B 18.20 10.98
INCY Incyte Corporation

+1.91 (+2.50%)

USD 16.44B 53.79 40.58
BMRN BioMarin Pharmaceutical Inc

+1.56 (+2.15%)

USD 13.04B N/A -203.31
GMAB Genmab A/S

+0.04 (+0.20%)

USD 12.96B N/A -0.00
SGEN Seattle Genetics, Inc

+0.48 (+0.68%)

USD 11.42B N/A -54.28
GLPG Galapagos NV

-2.76 (-1.71%)

USD 9.94B 72.40 0.00
ALNY Alnylam Pharmaceuticals, Inc

+1.08 (+1.29%)

USD 9.31B N/A -8.80
IONS Ionis Pharmaceuticals, Inc

-1.07 (-1.62%)

USD 9.30B 23.32 72.05

ETFs Containing BLU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.39B 64% D 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -38.36 91% A- 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -58.81% 57% F 20% F
Return on Invested Capital -25.77% 73% C 24% F
Return on Assets -32.86% 42% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.98 24% F 14% F
Short Percent N/A N/A N/A N/A N/A
Beta 1.37 57% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.